SSL-VQ: vector-quantized variational autoencoders for semi-supervised prediction of therapeutic targets across...

Identifying effective therapeutic targets poses a challenge in drug discovery, especially for uncharacterized diseases without known therapeutic targets (e.g. rare diseases, intractable diseases).

This study presents a novel machine learning approach using multimodal vector-quantized variational autoencoders (VQ-VAEs) for predicting therapeutic target molecules across diseases. To address the lack of known therapeutic target-disease associations, we incorporate the information on uncharacterized diseases without known targets or uncharacterized proteins without known indications (applicable diseases) in the semi-supervised learning (SSL) framework. The method integrates disease-specific and protein perturbation profiles with genetic perturbations (e.g. gene knockdowns and gene overexpressions) at the transcriptome level. Cross-cell representation learning, facilitated by VQ-VAEs, was performed to extract informative features from protein perturbation profiles across diverse human cell types. Concurrently, cross-disease representation learning was performed, leveraging VQ-VAE, to extract informative features reflecting disease states from disease-specific profiles. The model's applicability to uncharacterized diseases or proteins is enhanced by considering the consistency between disease-specific and patient-specific signatures. The efficacy of the method is demonstrated across three practical scenarios for 79 diseases: target repositioning for target-disease pairs, new target prediction for uncharacterized diseases, and new indication prediction for uncharacterized proteins. This method is expected to be valuable for identifying therapeutic targets across various diseases.

Code: github.com/YamanishiLab/SSL-VQ and Data: 10.5281/zenodo.14644837.